Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:57 PM
Ignite Modification Date:
2025-12-24 @ 9:57 PM
NCT ID:
NCT04766632
Eligibility Criteria:
Inclusion Criteria:
* Adult \> 18 and \< 75 years old
* Status WHO ≤ 2
* Histological diagnosis of WHO grade III or IV glioma, in local recurrence after radiochemotherapy (60Gy/30 sessions + concomitant TEMOZOLOMIDE), postoperatively or exclusively.
* Recurrence in the field of initial radiotherapy
* Indication for stereotactic radiotherapy alone, validated in neuro-oncology CPR.
* Patient affiliated to a social security system
* Patient able to give consent
Exclusion Criteria:
* Contraindication to new radiotherapy
* First treatment other than standard radiochemotherapy (60Gy/30 session + concomitant TEMOZOLOMIDE), postoperative or exclusive.
* Contraindication to MRI and/or gadolinium injection
* Pregnancy, breastfeeding
* Follow-up of the patient impossible
* Persons deprived of liberty or under guardianship
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT04766632
Study Brief:
Protocol Section:
NCT04766632